ITPP
Myo-inositol trispyrophosphate
ITPP (Myo-inositol trispyrophosphate) is a metabolic & fat loss research compound. Allosteric effector of hemoglobin — shifts the oxygen-dissociation curve so red cells release more O2 to tissue; endurance/hypoxia angle.
ITPP quick facts
| Reported research dose | 500mg-2000mg |
| Route | Subq |
| Frequency | 1x Daily AM · 5 On 2 Off or Daily |
| Half-life | Short (rapid renal clearance) |
| Forms | Oral |
| Evidence level | Animal |
Oxygen-delivery play for endurance. Fascinating, firmly research-stage.
How ITPP works
Allosteric effector of hemoglobin — shifts the oxygen-dissociation curve so red cells release more O2 to tissue; endurance/hypoxia angle.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Human clinical evidence
- No human trials. It never left preclinical development, so the ceiling on what anyone can claim is a rodent model — and rodent models of this endpoint have a poor record of transferring.
📊 Correlative data
- Known primarily through equine doping — it was detected in racehorses and prompted regulatory action in several jurisdictions, and it is on the WADA prohibited list for human sport.
- Human research-market use is limited and the reported experience is unreliable, because the claimed effect — altered oxygen offloading — is not something you can perceive directly.
- Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 How the mechanism reads
- An allosteric effector of haemoglobin. It enters red cells and binds haemoglobin at the 2,3-BPG site, shifting the oxygen dissociation curve rightward — meaning haemoglobin holds oxygen less tightly and releases more of it to tissue at any given partial pressure.
- This is the opposite strategy to EPO: rather than carrying more oxygen, deliver more of what is already carried. In tumour models it was studied for reducing hypoxia, which is where the original research interest came from.
- A rightward shift has a hard ceiling and a real cost. Shifted too far, haemoglobin fails to load properly in the lungs — the same curve that improves unloading impairs uptake, and nobody has established where that crossover sits in humans.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
ITPP — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Beta-2 agonists (clenbuterol, albuterol) and central stimulants (tesofensine) share one predicted problem: cardiac load. Raised heart rate, palpitations, tremor and insomnia are the mechanism showing up, not an idiosyncratic reaction.
- Beta-2 agonists drive potassium into cells, so hypokalaemia is predicted — and low potassium is itself arrhythmogenic, which is how a stimulant side effect becomes a cardiac one.
- Clenbuterol's half-life is long (well over a day in humans), so it accumulates across daily dosing. The dose that felt fine on day one is not the exposure you have on day five.
- Beta-2 receptors downregulate within around two weeks — the thermogenic effect fades while the cardiac effect persists longer. That is the worst possible combination and it is why escalating the dose to chase the original effect is the dangerous move.
What has actually been reported
- Cardiac hypertrophy is documented in animal models at sustained high doses. Human data comes largely from poisoning case reports — tachycardia, tremor, hypokalaemia, and arrhythmia.
- Tesofensine raised blood pressure and heart rate in trials, which is part of why its development for obesity stalled.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Take a resting heart rate every morning. It moves before anything else does and it is a better early signal than any quarterly panel.
- Potassium and magnesium intake matter here specifically because of the intracellular shift — this is one of the few places a supplement addresses the actual mechanism rather than a vague deficiency.
- Do not escalate to recover a faded effect. The fade is receptor downregulation, and the answer is a break, not more.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Potassium and magnesium (a CMP covers potassium). Blood pressure and resting heart rate are the real monitoring and they are free.
Don't run this if
- You have any arrhythmia, structural heart disease, or uncontrolled hypertension.
- You are already taking another stimulant, including high-dose caffeine — the cardiac effects are additive and people do not count coffee.
The honest unknown
- Whether the cardiac hypertrophy seen in animals occurs at the doses and durations used in humans is not established, and it would be difficult to study ethically.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get ITPP
Buy ITPP at Disguised Alpha →ITPP — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What ITPP moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for ITPP — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
Get the complete breakdown for ITPP — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside ITPP
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 102 markers A–Z
ITPP — frequently asked questions
What is ITPP?
ITPP (Myo-inositol trispyrophosphate) is a metabolic & fat loss research compound. Allosteric effector of hemoglobin — shifts the oxygen-dissociation curve so red cells release more O2 to tissue; endurance/hypoxia angle.
Is the full ITPP protocol on this page?
The reported research dose is on this page, along with how ITPP works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of ITPP?
ITPP has an approximate half-life of Short (rapid renal clearance), which is part of what determines how often it's dosed.
What's the evidence behind ITPP?
Current evidence level: Animal. ITPP is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact ITPP protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What ITPP is used for
ITPP appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.